Orchard Therapeutics: Funding, Investors & Team (Oct 2026)
Orchard Therapeutics is a company committed to improving the lives of patients with rare diseases through the use of innovative gene therapies. Their portfolio of autologous ex vivo gene therapy programs has been successful in producing long-term clinical benefits for over 150 patients across five different disease areas. The company has several ongoing programs, including Strimvelis®, the first gene therapy of its kind to be approved by the EMA in 2016, as well as other clinical and preclinical programs. Orchard has formed partnerships with several well-respected institutions in the field of gene therapy, and the company is publicly traded on the NASDAQ. With offices in the UK and the US, Orchard is well-positioned to continue making advancements in gene therapy research and development.
Orchard Therapeutics has raised $34.0M across 1 funding round on record, the most recent an undisclosed round of $34.0M announced in Mar 2023.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Orchard Therapeutics Company Profile and Key Stats
Latest funding round on record: Mar 2023.
Orchard Therapeutics Funding Rounds
Orchard Therapeutics Founders and Leadership Team
Contact details for the Orchard Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Orchard Therapeutics Funding Compared to Other Biotechnology Startups
Orchard Therapeutics' latest round of $34.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Orchard Therapeutics in Biotechnology and London
Companies Similar to Orchard Therapeutics
Microbiotica develops treatments involving live bacteria found in the human microbiome, aiming to identify…
OMass Technologies is a drug discovery company exploiting novel mass spectrometry platforms to develop…
HydRegen, based in Oxford, UK, is a biotech firm that offers eco-friendly alternatives for the production of…
R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug…
The perfect package for any general surgical trainee or resident. Progress from beginner to advanced surgical…
Argonaute RNA company research projects build on existing intellectual property.
An innovative C elegans company that serves the biotech, nutrition, and other industries and fields of study…
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
Orchard Therapeutics Funding FAQs
What does Orchard Therapeutics do?
Orchard Therapeutics is a company committed to improving the lives of patients with rare diseases through the use of innovative gene therapies. Their portfolio of autologous ex vivo gene therapy programs has been successful in producing long-term clinical benefits for over 150 patients across five different disease areas. The company has several ongoing programs, including Strimvelis®, the first gene therapy of its kind to be approved by the EMA in 2016, as well as other clinical and preclinical programs. Orchard has formed partnerships with several well-respected institutions in the field of gene therapy, and the company is publicly traded on the NASDAQ. With offices in the UK and the US, Orchard is well-positioned to continue making advancements in gene therapy research and development.
How much funding has Orchard Therapeutics raised?
Orchard Therapeutics has raised $34.0M across 1 round on record. The most recent is an undisclosed round of $34.0M announced in Mar 2023.
When did Orchard Therapeutics last raise funding?
Orchard Therapeutics' most recent funding round on record is an undisclosed round of $34.0M, announced in Mar 2023.
Who is the CEO of Orchard Therapeutics?
Bobby Gaspar is listed as CEO at Orchard Therapeutics.
Where is Orchard Therapeutics headquartered?
Orchard Therapeutics is based in London, England, United Kingdom.
How many employees does Orchard Therapeutics have?
Orchard Therapeutics is in the 101-250 employee band.
How does Orchard Therapeutics' funding compare to other Biotechnology startups?
Orchard Therapeutics' latest round of $34.0M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Orchard Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Orchard Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.